Analytical Data
-
基因名
CLEC10A/CD301
-
简介
The CLEC10A/CD301 protein is a receptor that recognizes terminal galactose and N-acetylgalactosamine units and is involved in a variety of biological processes.It may play a crucial role by promoting interactions between tumor-killing macrophages and tumor cells.CLEC10A/CD301 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CLEC10A/CD301 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
别名
C-type lectin domain family 10 member A; CD301; CLEC10A; CLECSF13; CLECSF14; HML
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P49300
-
表达区间
Q57-S304
-
蛋白长度
Extracellular Domain
-
分子量
38-45 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC10A, also known as CD301, is a C-type lectin receptor predominantly expressed on dendritic cells and macrophages, playing a crucial role in the immune system by recognizing and binding to specific carbohydrate structures on pathogens. Research on CLEC10A/CD301 has gained momentum due to its involvement in innate immune responses and its potential as a therapeutic target in various diseases, including infections and cancer. The receptor is known to modulate immune responses by engaging with different ligands, leading to the activation of various signaling pathways. Recombining CLEC10A/CD301 as a recombinant protein allows for detailed studies of its biological functions, interactions, and potential applications in immunotherapy. Investigating this protein's structure and function can aid in understanding its role in immune modulation and could provide insights into novel vaccine development strategies. Additionally, the exploration of CLEC10A/CD301's interactions with glycosylated molecules expands the knowledge base surrounding pathogen recognition and the immune response, establishing a solid foundation for future research in immunology and therapeutic interventions.
